<DOC>
	<DOCNO>NCT02763215</DOCNO>
	<brief_summary>This 24-month study ass copper ( Cu ) parameter subject Wilson Disease treat standard care ( SOC ) medication . Data collect routinely schedule Wilson Disease clinic visit approximately 6-month interval . After provide informed consent , subject meet inclusion exclusion criterion enrol study outpatient . Subject 's routine Wilson Disease clinic visit schedule accord standard clinical practice study center discretion treat physician approximate 6-month interval . At time enrollment , subject receive SOC therapeutic agent treatment Wilson Disease . If treatment interrupt stop course study , subject continue study biological sample clinical data continue collect full 24-month study period . Dosing SOC agent , include penicillamine , trientine , zinc , combination Cu chelator zinc , individualize manage treat physician study center accord standard clinical practice site .</brief_summary>
	<brief_title>The Assessment Copper Parameters Wilson Disease Subjects Standard Care Treatment</brief_title>
	<detailed_description />
	<mesh_term>Hepatolenticular Degeneration</mesh_term>
	<mesh_term>Copper</mesh_term>
	<criteria>Willing able give inform consent participation study . Male female subject , age 18 year old sign ICF . Receiving Standard Care therapeutic agent ( penicillamine , trientine , zinc , copper chelators zinc ) treatment Wilson Disease time enrollment 60 month prior enrollment . Able understand willing comply study procedures requirement , judge Investigator . Established diagnosis Wilson Disease . Adequate venous access allow collection blood sample . Major systemic disease illness would , opinion Investigator , compromise subject safety interfere collection interpretation study result . In opinion Investigator , subject likely noncompliant uncooperative study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>